15 known cases. View patent page →
Federal Circuit appeal from the PTAB IPR decision on U.S. 8,589,182. The court affirmed, holding the FDA Advisory Committee materials were a publicly accessible printed publication and proper prior art; the decision disposed of the family patents together.
Inter partes review petitioned by Amneal Pharmaceuticals, LLC et al. against Jazz Pharmaceuticals, Inc. The PTAB held all claims of US 7,765,107 unpatentable as obvious in a Final Written Decision on July 27, 2016; Jazz appealed and the Federal Circuit affirmed.
Inter partes review petitioned by Wockhardt Bio AG et al. against Jazz Pharmaceuticals, Inc., joined/consolidated with IPR2015-00547. Proceedings terminated as to Wockhardt Bio AG on May 5, 2016 after a confidential settlement, with Final Written Decision on July 27, 2016 in the consolidated proceeding.
Covered business method review petitioned by Roxane Laboratories, Inc. et al. against Jazz Pharmaceuticals Inc. challenging US 7,765,107; institution was denied on February 9, 2015.
Lead/first ANDA Hatch-Waxman case filed by Jazz Pharmaceuticals against Roxane Laboratories. The complaint expressly asserted US 7,765,107 along with other patents ('889, '219, '730, '106); the '107 claims were later invalidated via IPR2015-00547.
ANDA Hatch-Waxman action by Jazz Pharmaceuticals against Par Pharmaceuticals involving Xyrem and US 7,765,107. Par's Paragraph IV notice was dated November 20, 2013; the case later settled on January 9, 2018 with an authorized-generic license.
ANDA Hatch-Waxman action by Jazz Pharmaceuticals and others against Lupin Ltd. and others involving Xyrem and US 7,765,107. Complaint filed September 1, 2015; case terminated January 15, 2016.
Listed on the patent record as a consolidated Xyrem ANDA action associated with US 7,765,107. Individual caption, parties, filing date, and outcome are not confirmed.
Consolidated multidistrict antitrust litigation challenging Xyrem patent-settlement and REMS conduct. US 7,765,107 is listed among the patents at issue in the narrative, but the antitrust actions do not assert the patent.
Xyrem antitrust class action related to the Xyrem MDL; US 7,765,107 is listed among the patents at issue in the narrative.
Xyrem antitrust action related to the Xyrem MDL; US 7,765,107 is listed among the patents at issue in the narrative.
Xyrem antitrust action filed in N.D. Ill. and terminated July 22, 2020 when transferred to the Xyrem MDL. US 7,765,107 is listed among the patents at issue in the narrative.
Xyrem antitrust action; US 7,765,107 is listed among the patents at issue in the narrative.
Xyrem antitrust action; US 7,765,107 is listed among the patents at issue in the narrative.
Jazz Pharmaceuticals sued Ranbaxy Laboratories and Ranbaxy Inc. in a Hatch-Waxman ANDA patent infringement action over generic sodium oxybate referencing Xyrem. The complaint asserted multiple patents including U.S. Patent No. 8,461,203. The case was consolidated for all purposes into Jazz Pharmaceuticals, Inc. v. Amneal Pharmaceuticals, LLC, No. 13-391-ES-JAD, and administratively terminated.